Kezar’s decision to terminate the PALIZADE IIb trial comes after it was placed on a clinical hold due to four patient deaths.

Kezar Life Sciences (NASDAQ:KZR) is discontinuing development of its drug zetomipzomib for the treatment of lupus nephritis ...

Kezar Life Sciences announced the termination of Phase 2b PALIZADE clinical trial of zetomipzomib, an investigational therapy ...

William Blair analyst Matt Phipps in a note to investors wrote that despite the patient deaths, the totality of the data ...

The regulator's decision came after the company paused the study in September to review safety data following the deaths of ...

FDA placed Kezar’s lupus nephritis drug on clinical hold after four fatal adverse events. Kezar says the autoimmune hepatitis ...

Earlier this month, Kezar Life Sciences announced that the mid-stage test of zetomipzomib in lupus nephritis had been placed ...

The FDA has placed Kezar Life Sciences’ lupus trial on hold after the biotech flagged four deaths during the phase 2b study.

On Thursday, Kezar Life Sciences, Inc (NASDAQ:KZR) decided to terminate the PALIZADE Phase 2b trial in patients with active ...

The REGENCY study met its primary endpoint, demonstrating statistically significant and clinically meaningful treatment benefits in people with active lupus nephritis – – Gazyva is designed to ...

Preconception predictors of adverse pregnancy outcomes among women with SLE include previous lupus nephritis, chronic hypertension, SLE disease activity, and APS.